Tetralogic Pharmaceuticals Corp Company Profile (NASDAQ:TLOG)

About Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)

Tetralogic Pharmaceuticals Corp logoTetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company's segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company's histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $1.03 million
  • Outstanding Shares: 24,769,000
Average Prices:
  • 50 Day Moving Avg: $0.03
  • 200 Day Moving Avg: $0.03
  • 52 Week Range: $0.02 - $0.17
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.04
  • P/E Growth: 0.00000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: ($1.25) per share
  • Price / Book: -0.03
  • EBITDA: ($21,140,000.00)
  • Return on Assets: -73.81%
  • Debt-to-Equity Ratio: -1.00%
  • Current Ratio: 0.48%
  • Quick Ratio: 0.48%
  • Average Volume: 70,642 shs.
  • Beta: 3
  • Short Ratio: 4.39

Frequently Asked Questions for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)

What is Tetralogic Pharmaceuticals Corp's stock symbol?

Tetralogic Pharmaceuticals Corp trades on the NASDAQ under the ticker symbol "TLOG."

How were Tetralogic Pharmaceuticals Corp's earnings last quarter?

Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) released its quarterly earnings data on Thursday, February, 26th. The company reported ($0.53) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.39) by $0.14. View Tetralogic Pharmaceuticals Corp's Earnings History.

When will Tetralogic Pharmaceuticals Corp make its next earnings announcement?

Tetralogic Pharmaceuticals Corp is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Tetralogic Pharmaceuticals Corp.

Who are some of Tetralogic Pharmaceuticals Corp's key competitors?

Who are Tetralogic Pharmaceuticals Corp's key executives?

Tetralogic Pharmaceuticals Corp's management team includes the folowing people:

  • Andrew L. Pecora M.D., Independent Chairman of the Board

How do I buy Tetralogic Pharmaceuticals Corp stock?

Shares of Tetralogic Pharmaceuticals Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tetralogic Pharmaceuticals Corp's stock price today?

One share of Tetralogic Pharmaceuticals Corp stock can currently be purchased for approximately $0.04.

MarketBeat Community Rating for Tetralogic Pharmaceuticals Corp (NASDAQ TLOG)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  52 (Vote Outperform)
Underperform Votes:  33 (Vote Underperform)
Total Votes:  85
MarketBeat's community ratings are surveys of what our community members think about Tetralogic Pharmaceuticals Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
Price Target History for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
Analysts' Ratings History for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
1/7/2016Roth CapitalLower Price TargetBuy$5.00 -> $1.00N/AView Rating Details
(Data available from 10/22/2015 forward)


Earnings History for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
Earnings by Quarter for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
Earnings History by Quarter for Tetralogic Pharmaceuticals Corp (NASDAQ TLOG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2015Q414($0.39)($0.53)$1.13 millionViewN/AView Earnings Details
11/5/2014Q314($4.34)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
Current Year EPS Consensus Estimate: $-1.77000 EPS
Next Year EPS Consensus Estimate: $-0.99000 EPS


Dividend History for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
Insider Ownership Percentage: 24.00%
Institutional Ownership Percentage: 2.69%
Insider Trades by Quarter for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
Insider Trades by Quarter for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/9/2016Lifesciences Ii L.P. ClarusMajor ShareholderSell333,630$0.17$56,717.10View SEC Filing  
2/5/2016Lifesciences Ii L.P. ClarusMajor ShareholderSell1,415,490$0.18$254,788.20View SEC Filing  
2/2/2016Lifesciences Ii L.P. ClarusMajor ShareholderSell369,132$0.19$70,135.08View SEC Filing  
1/28/2016Lifesciences Ii L.P. ClarusMajor ShareholderSell311,930$0.28$87,340.40View SEC Filing  
7/10/2015Andrew L PecoraDirectorBuy50,000$2.68$134,000.00View SEC Filing  
7/9/2015Andrew L PecoraDirectorBuy50,000$2.40$120,000.00View SEC Filing  
7/2/2015Paul J SchmittDirectorBuy10,000$2.34$23,400.00View SEC Filing  
3/27/2015Pete A MeyersCFOBuy5,000$4.35$21,750.00View SEC Filing  
3/26/2015J Kevin BuchiCEOBuy5,000$4.23$21,150.00View SEC Filing  
1/7/2015J Kevin BuchiCEOBuy5,000$5.04$25,200.00View SEC Filing  
12/10/2014Colin Glenn BegleySVPBuy5,900$6.16$36,344.00View SEC Filing  
12/9/2014J Kevin BuchiCEOBuy5,000$6.01$30,050.00View SEC Filing  
12/4/2014Pete A MeyersCFOBuy1,034$4.94$5,107.96View SEC Filing  
12/2/2014J Kevin BuchiCEOBuy10,000$4.99$49,900.00View SEC Filing  
11/26/2014Colin Glenn BegleySVPBuy3,100$4.86$15,066.00View SEC Filing  
11/26/2014Lesley RussellCOOBuy20,000$4.90$98,000.00View SEC Filing  
11/25/2014Colin Glenn BegleySVPBuy2,000$4.85$9,700.00View SEC Filing  
11/18/2014J Kevin BuchiCEOBuy10,000$4.82$48,200.00View SEC Filing  
11/17/2014Andrew L PecoraDirectorBuy20,000$4.53$90,600.00View SEC Filing  
11/12/2014Peter A MeyersCFOBuy5,000$3.98$19,900.00View SEC Filing  
11/11/2014J Kevin BuchiCEOBuy10,000$3.93$39,300.00View SEC Filing  
11/10/2014Paul J SchmittDirectorBuy20,000$4.10$82,000.00View SEC Filing  
12/17/2013J Kevin BuchiCEOBuy285,714$7.00$1,999,998.00View SEC Filing  
12/17/2013James N WoodyDirectorBuy261,427$7.00$1,829,989.00View SEC Filing  
12/17/2013Peter A MeyersCFOBuy142,857$7.00$999,999.00View SEC Filing  
12/17/2013Ventures Vii Lp HealthcareMajor ShareholderBuy713,463$7.00$4,994,241.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
Latest Headlines for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
Loading headlines, please wait.



Tetralogic Pharmaceuticals Corp (TLOG) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.